These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10786353)

  • 21. Possible lansoprazole-induced eosinophilic syndrome.
    Smith JD; Chang KL; Gums JG
    Ann Pharmacother; 1998 Feb; 32(2):196-200. PubMed ID: 9496405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
    Arroyo Villarino MT; Lanas Arbeloa A; Esteva Díaz F; Ortego Fernández de Retana J; Sainz Samitier R
    Rev Esp Enferm Dig; 1997 May; 89(5):347-56. PubMed ID: 9190140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diarrhea associated with lansoprazole.
    Mukherjee S
    J Gastroenterol Hepatol; 2003 May; 18(5):602-3. PubMed ID: 12702056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
    Vcev A; Stimac D; Vceva A; Rubinić M; Ivandić A; Ivanis N; Horvat D; Volarić M; Karner I
    Acta Med Croatica; 1997; 51(3):171-4. PubMed ID: 9248117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
    Leonhardt U; Ritzel U; Ramadori G
    Internist (Berl); 1996 Sep; 37(9):944-9; discussion 949. PubMed ID: 8964694
    [No Abstract]   [Full Text] [Related]  

  • 26. Proton-pump inhibitors: three of a kind?
    Bateman DN
    Lancet; 1997 Jun; 349(9066):1637-8. PubMed ID: 9186377
    [No Abstract]   [Full Text] [Related]  

  • 27. [Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
    Müller P; Fuchs W; Peifer-Weiss A; Simon B
    Fortschr Med; 1998 Oct; 116(28):31-2. PubMed ID: 9844264
    [No Abstract]   [Full Text] [Related]  

  • 28. Fatal toxic epidermal necrolysis due to lansoprazole.
    Revuz J
    Clin Exp Dermatol; 2006 Jan; 31(1):148. PubMed ID: 16309521
    [No Abstract]   [Full Text] [Related]  

  • 29. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM; Faulds D
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
    Martin RM; Dunn NR; Freemantle S; Shakir S
    Br J Clin Pharmacol; 2000 Oct; 50(4):366-72. PubMed ID: 11012560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of hemolysis induced by lansoprazole].
    Suzuki T; Hayashi T; Nonaka Y; Hirano M; Nomura T; Miyazawa I; Ishikawa F; Kakiuchi T
    Rinsho Ketsueki; 1996 Dec; 37(12):1389-94. PubMed ID: 8997127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
    Arnold R
    Fortschr Med; 1994 Jan; 112(1-2):44-5. PubMed ID: 8144120
    [No Abstract]   [Full Text] [Related]  

  • 36. Acute manic psychosis induced by triple therapy for H. pylori.
    Neff NE; Kuo G
    J Am Board Fam Pract; 2002; 15(1):66-8. PubMed ID: 11841141
    [No Abstract]   [Full Text] [Related]  

  • 37. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
    Haga Y; Nakatsura T; Shibata Y; Sameshima H; Nakamura Y; Tanimura M; Ogawa M
    Dig Dis Sci; 1998 Feb; 43(2):253-7. PubMed ID: 9512115
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety profile of Lansoprazole: the US clinical trial experience.
    Freston JW; Rose PA; Heller CA; Haber M; Jennings D
    Drug Saf; 1999 Feb; 20(2):195-205. PubMed ID: 10082075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
    Agrawal NM; Campbell DR; Safdi MA; Lukasik NL; Huang B; Haber MM
    Arch Intern Med; 2000 May; 160(10):1455-61. PubMed ID: 10826458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach.
    Stolte M; Meining A; Seifert E; Alexandridis T
    Pathol Res Pract; 2000; 196(1):9-13. PubMed ID: 10674267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.